Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma

Domenico Albano; Giuseppe Micci; Caterina Patti; Federico Midiri; Silvia Albano; Giuseppe Lo Re; Emanuele Grassedonio; Ludovico La Grutta; Roberto Lagalla; Massimo Galia

doi:10.3390/diagnostics11061007

journal article Open Access May 31, 2021

Whole-Body Magnetic Resonance Imaging: Current Role in Patients with Lymphoma

Domenico Albano

Giuseppe Micci Caterina Patti Federico Midiri Silvia Albano Giuseppe Lo Re

Emanuele Grassedonio Ludovico La Grutta Roberto Lagalla Massimo Galia

Diagnostics Vol. 11 No. 6 pp. 1007 · MDPI AG

View at Publisher Save 10.3390/diagnostics11061007

Abstract

Imaging of lymphoma is based on the use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) and/or contrast-enhanced CT, but concerns have been raised regarding radiation exposure related to imaging scans in patients with cancer, and its association with increased risk of secondary tumors in patients with lymphoma has been established. To date, lymphoproliferative disorders are among the most common indications to perform whole-body magnetic resonance imaging (MRI). Whole-body MRI is superior to contrast-enhanced CT for staging the disease, also being less dependent on histology if compared to 18F-FDG-PET/CT. As well, it does not require exposure to ionizing radiation and could be used for the surveillance of lymphoma. The current role of whole-body MRI in the diagnostic workup in lymphoma is examined in the present review along with the diagnostic performance in staging, response assessment and surveillance of different lymphoma subtypes.

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Siegel "Cancer statistics, 2012" CA Cancer J. Clin. (2012) 10.3322/caac.20138

[2]

Siegel "Cancer Incidence Rates and Trends Among Children and Adolescents in the United States, 2001–2009" Pediatrics (2014) 10.1542/peds.2013-3926

[3]

Jaffe "Diagnosis and classification of lymphoma: Impact of technical advances" Semin. Hematol. (2019) 10.1053/j.seminhematol.2018.05.007

[4]

Shanbhag "Hodgkin lymphoma: A review and update on recent progress" CA Cancer J. Clin. (2018) 10.3322/caac.21438

[5]

Shah "Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful" Korean J. Radiol. (2017) 10.3348/kjr.2017.18.1.54

[6]

Ceriani "Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study" Br. J. Haematol. (2017) 10.1111/bjh.14728

[7]

Lunning "Management of indolent lymphoma: Where are we now and where are we going" Blood Rev. (2012) 10.1016/j.blre.2012.09.004

[8]

Armitage "Is watch and wait still acceptable for patients with low-grade follicular lymphoma?" Blood (2016) 10.1182/blood-2015-11-632745

[9]

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al.

Journal of Clinical Oncology 2014 10.1200/jco.2013.54.8800

[10]

Gallamini "Fdg-Pet scan: A new paradigm for follicular lymphoma management" Mediterr. J. Hematol. Infect. Dis. (2016) 10.4084/mjhid.2017.029

[11]

Chien "Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study" Int. J. Cancer (2015) 10.1002/ijc.29433

[12]

Huang "Whole-Body PET/CT Scanning: Estimation of Radiation Dose and Cancer Risk" Radiology (2009) 10.1148/radiol.2511081300

[13]

Albano "Whole-body magnetic resonance imaging (WB-MRI) in oncology: An Italian survey" La Radiol. Med. (2021) 10.1007/s11547-020-01242-7

[14]

Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma

Alessandro Stecco, Francesco Buemi, Antoine Iannessi et al.

Leukemia & Lymphoma 2018 10.1080/10428194.2018.1434881

[15]

Lister "Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting" J. Clin. Oncol. (1989) 10.1200/jco.1989.7.11.1630

[16]

Mylam "Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients with Hodgkin Lymphoma" J. Clin. Oncol. (2012) 10.1200/jco.2012.42.4036

[17]

Zinzani "Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma" J. Clin. Oncol. (2009) 10.1200/jco.2008.16.1513

[18]

Galia "Whole-body MRI in patients with lymphoma: Collateral findings" La Radiol. Med. (2016) 10.1007/s11547-016-0658-x

[19]

Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations

Anwar R. Padhani, Guoying Liu, Dow Mu-Koh et al.

Neoplasia 2009 10.1593/neo.81328

[20]

Kwee "Imaging in staging of malignant lymphoma: A systematic review" Blood (2008) 10.1182/blood-2007-07-101899

[21]

Morone, M., Bali, M.A., Tunariu, N., Messiou, C., Blackledge, M., Grazioli, L., and Koh, D.-M. (2017). Whole-Body MRI: Current Applications in Oncology. Am. J. Roentgenol., 209. 10.2214/ajr.17.17984

[22]

Pozzi "Solid bone tumors of the spine: Diagnostic performance of apparent diffusion coefficient measured using diffusion-weighted MRI using histology as a reference standard" J. Magn. Reson. Imaging (2017) 10.1002/jmri.25826

[23]

Albano "Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: What radiologists should know" Magn. Reson. Imaging (2016) 10.1016/j.mri.2016.04.023

[24]

Mayerhoefer "Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients" Clin. Cancer Res. (2014) 10.1158/1078-0432.ccr-13-3355

[25]

Punwani "Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease" Pediatr. Radiol. (2013) 10.1007/s00247-012-2616-7

[26]

Littooij "Accuracy of whole-body MRI in the assessment of splenic involvement in lymphoma" Acta Radiol. (2015) 10.1177/0284185115571657

[27]

Doniselli "Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: What rheumatologists should know" Clin. Rheumatol. (2017) 10.1007/s10067-017-3604-y

[28]

Savarino "Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn’s disease?" Dig. Liver Dis. (2017) 10.1016/j.dld.2017.04.010

[29]

Azzedine "Whole-body diffusion-weighted MRI for staging lymphoma at 3.0T: Comparative study with MR imaging at 1.5T" Clin. Imaging (2015) 10.1016/j.clinimag.2014.06.017

[30]

Whole-body MRI versus <sup>18</sup>F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis

Danyang Wang, Yanlei Huo, Suyun Chen et al.

OncoTargets and Therapy 2018 10.2147/ott.s148189

[31]

Moskowitz "Interim PET-CT in the management of diffuse large B-cell lymphoma" Hematology (2012) 10.1182/asheducation.v2012.1.397.3798512

[32]

Albano "Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma" J. Magn. Reson. Imaging (2017) 10.1002/jmri.25439

[33]

Albano "Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas" Eur. J. Radiol. (2016) 10.1016/j.ejrad.2015.12.006

[34]

Lin "Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma" Eur. Radiol. (2010) 10.1007/s00330-010-1758-y

[35]

Abdulqadhr "Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients" Acta Radiol. (2011) 10.1258/ar.2010.100246

[36]

Kwee "Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: Comparison with CT in a prospective multicenter study" J. Magn. Reson. Imaging (2014) 10.1002/jmri.24356

[37]

Cirillo "Whole-body MRI with diffusion-weighted imaging: A valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma" Clin. Radiol. (2016) 10.1016/j.crad.2015.11.018

[38]

Stecco "Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and18F-FDG-PET/CT" Gastroenterol. Res. Pr. (2015) 10.1155/2015/104794

[39]

Stecco, A., Trisoglio, A., Soligo, E., Berardo, S., Sukhovei, L., and Carriero, A. (2018). Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review. Diagnostics, 8. 10.3390/diagnostics8030045

[40]

Adams "Whole-body MRI for the detection of bone marrow involvement in lymphoma: Prospective study in 116 patients and comparison with FDG-PET" Eur. Radiol. (2013) 10.1007/s00330-013-2835-9

[41]

Haddy "Bone marrow involvement in young patients with non-Hodgkin’s lymphoma: The importance of multiple bone marrow samples for accurate staging" Med. Pediatr. Oncol. (2006) 10.1002/mpo.2950170512

[42]

Gallamini "Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin’s Lymphoma: A Report From a Joint Italian-Danish Study" J. Clin. Oncol. (2007) 10.1200/jco.2007.11.6525

[43]

Gallamini "Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial" J. Clin. Oncol. (2018) 10.1200/jco.2017.75.2543

[44]

Albano "Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD" Eur. J. Radiol. (2018) 10.1016/j.ejrad.2018.04.014

[45]

Horger "Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity—A preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging" Eur. J. Radiol. (2014) 10.1016/j.ejrad.2014.05.027

[46]

Latifoltojar "Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin’s lymphoma: A comparison with multi-modality reference standard including 18F-FDG-PET-CT" Eur. Radiol. (2018) 10.1007/s00330-018-5445-8

[47]

Lin "Whole-Body Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Treatment Response Assessment in Patients With Diffuse Large B-Cell Lymphoma" Investig. Radiol. (2011) 10.1097/rli.0b013e3182087b03

[48]

Bevernage "Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: A pilot study" Cancer Imaging (2013) 10.1102/1470-7330.2013.0006

[49]

Mayerhoefer "Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT–Controlled Prospective Study in 64 Patients" Clin. Cancer Res. (2015) 10.1158/1078-0432.ccr-14-2454

[50]

Brenner "Survival Expectations of Patients Diagnosed with Hodgkin’s Lymphoma in 2006–2010" Oncologist (2009) 10.1634/theoncologist.2008-0285

Showing 50 of 59 references

Metrics

12

Citations

59

References

Details

Published: May 31, 2021
Vol/Issue: 11(6)
Pages: 1007
License: View

Authors

D

Domenico Albano

Sezione di Scienze Radiologiche, Dipartimento di Biomedicina, Neuroscienze e Diagnostica Avanzata, Università degli Studi di Palermo, 90133 Palermo, Italy; IRCCS Istituto Ortopedico Galeazzi, Unità Operativa di Radiologia Diagnostica ed Interventistica, 20161 Milan, Italy

G

Giuseppe Micci